Comparison of Carboplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients With Morbidity Risks

Abstract

Purpose. The aim of this study was to assess the activity and toxicity of primary carboplatin-based chemoradiotherapy (CarboRT) Implications for Practice: Cisplatin-based chemoradiotherapy (CisRT) has been regarded as the standard treatment for patients with locally advanced cervical cancer. Cisplatin, however, can cause nephrotoxicity, has highly emetogenic effects, and creates the need for a large amount of hydration. Carboplatin-based chemoradiotherapy was better tolerated than CisRT without compromising tumor response and survival in patients with locally advanced cervical cancer and poor general condition.

Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials

“…Sebastião [14] showed that single-agent cisplatin and carboplatin plus RT have similar survival benefits and toxicity. The study conducted by Nam [15] et al also supports this conclusion. For patients who cannot receive cisplatin, carboplatin may be an alternative treatment.…”

Definitive chemoradiotherapy for advanced cervical cancer: should it be different in the elderly?

“…Currently, most of the data directly comparing carboplatin and CDDP as radiosensitizers are originated from small, non randomized or uncontrolled trials. Despite these limitations, one study compared both CRT regimens and demonstrated that carboplatin appears to be equally effective and less toxic than cisplatin [23]. Therefore, carboplatin may be an alternative when treating patients with multiple comorbidities or kidney dysfunction.…”

Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: A case report

“…In India, it accounts for 16% of all cancers in urban women and 37% of the cancers in rural women (3). Concurrent chemoradiation using cisplatin has shown 30-50% reduction in the risk of death, and is regarded the standard treatment for patients with cervical cancer (7,14,15). Carboplatin, an analogue of cisplatin, with a similar mechanism of action, has been used for the treatment of locally advanced cervical carcinoma.…”

“…It has advantages over cisplatin in terms of decreased nephrotoxicity, neurotoxicity and emetogenesis (16). This favourable toxicity profile when compared to cisplatin may result in better patient adherence to the treatment plan (15). A phase II clinical study in patients with recurrent or metastatic squamous carcinoma of the uterine cervix revealed substantially better toxicity profile of carboplatin than cisplatin with similar efficacy (17).…”